The following video is part of our "Motley Fool Conversations" series in which technology editor/analyst Andrew Tonner and health-care editor/analyst David Williamson discuss topics across the investing world.
In this video, Andrew and David sit down to talk about the continuing acquisitions Big Pharma is making to acquire next gen hepatitis-C treatments. They go over the most recent deal, Bristol-Myers Squibb's $2.5 billion purchase of Inhibitex, compare it to Gilead's purchase of Pharmasset, and discuss which company would be next at the altar if buyout mania keeps going.
David Williamson and Andrew Tonner have no positions in the stocks mentioned above. The Motley Fool owns shares of Gilead Sciences. Motley Fool newsletter services recommend Gilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Top Healthcare Stocks to Buy in January
These prominent drug developers look to be enticing buys this month.
Should You Buy Bristol-Myers Squibb Stock in 2018?
Bristol lagged behind its peers in 2017. Can its stock rebound in 2018?
Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb
Which stock wins in a head-to-head match-up between these two big drugmakers?